Center for Scientific Review; Notice of Closed Meeting, 4608 [08-275]
Download as PDF
<![CDATA[
4608
Federal Register / Vol. 73, No. 17 / Friday, January 25, 2008 / Notices
jlentini on PROD1PC65 with NOTICES
The invention also relates to PA
variants, and/or compositions thereof,
which are useful for eliciting an
immunogenic response in mammals,
particularly humans, including
responses that provide protection
against, or reduce the severity of,
infections caused by B. anthracis. The
vaccines claimed in this application are
intended for active immunization for
prevention of B. anthracis infection, and
for preparation of immune antibodies.
Application: Improved B. anthracis
vaccines.
Developmental Status: Phase I clinical
studies are being performed.
Inventors: Joseph Shiloach (NIDDK),
Stephen Leppla (NIDCR), Delia Ramirez
(NIDDK), Rachel Schneerson (NICHD),
John Robbins (NICHD).
Publication: DM Ramirez, et al.
Production, recovery and
immunogenicity of the protective
antigen from a recombinant strain of
Bacillus anthracis. J Ind Microbiol
Biotechnol. 2002 Apr;28(4):232–238.
Patent Status: U.S. Provisional
Application No. 60/344,505 filed 09
Nov 2001 (HHS Reference No. E–023–
2002/0–US–01); U.S. Patent Application
No. 10/290,712 filed 08 Nov 2002 (HHS
Reference No. E–023–2002/0–US–02).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The National Institutes of Health is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
methods of preparing Bacillus anthracis
protective antigen (PA) from a cell or
organism, particularly a recombinant
cell or microorganism, for use in
vaccines. Please contact Rochelle S.
Blaustein, J.D., at 301/451–3636 or
Rochelle.Blaustein@nih.gov for
additional information.
Chimeric Gag Pseudovirions
Description of Technology: The
human immunodeficiency virus (HIV) is
the causative agent of acquired
immunodeficiency syndrome (AIDS).
The HIV virion basically consists of a
viral core and envelope. The core
consists predominantly of gag- and polencoded proteins and the viral RNA.
Expression of recombinant Gag
precursor proteins can lead to assembly
and budding of virus-like particles
(pseudovirions). The production of Gagbased pseudovirions in mammalian and
insect cell systems using recombinant
virus vectors provides a novel
technology for engineering recombinant
VerDate Aug<31>2005
16:59 Jan 24, 2008
Jkt 214001
protein-based particulate vaccines for
HIV and other viruses. The
incorporation of additional viral or
cellular, peptides and polypeptides may
be advantageous in vaccine
preparations, since they may contain
antigenic epitopes that may play a role
in inducing protection from infection or
disease.
The subject invention provides
chimeric nucleic acids comprising a
retroviral gag sequence, a target nucleic
acid sequence derived from a nucleic
acid encoding a fusion partner, and a
frame shift site. Expression of the
chimeric gene cassette results in
packaging the fusion partner into the
Gag pseudovirion. Suitable fusion
partners can be derived from any
protein of interest which has a
biological activity or which elicits a
cellular or humoral immune response.
Applications: HIV vaccines and/or
therapeutics.
Development Status: Early stage.
Inventors: Gregory J. Tobin (NCI/
SAIC), et al.
Patent Status: U.S. Patent No.
6,099,847 issued 08 Aug 2000 (HHS
Reference No. E–105–1996/1–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Dated: January 14, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–1259 Filed 1–24–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
Name of Committee: Oncological Sciences
Integrated Review Group; Basic Mechanisms
of Cancer Therapeutics Study Section.
Date: January 28–29, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Lambratu Rahman, PhD,
Scientific Review Officer, Center for
Scientific Review; National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, 301–451–
3493, rahmanl@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, (HHS)
Dated: January 16, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–275 Filed 1–24–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Nutrition.
Date: January 31, 2008.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Abubakar A. Shaikh, PhD,
DVM, Scientific Review Administrator,
Center for Scientific Review, National
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 73, Number 17 (Friday, January 25, 2008)]
[Notices]
[Page 4608]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-275]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Oncological Sciences Integrated Review Group;
Basic Mechanisms of Cancer Therapeutics Study Section.
Date: January 28-29, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road, NW., Washington, DC 20015.
Contact Person: Lambratu Rahman, PhD, Scientific Review Officer,
Center for Scientific Review; National Institutes of Health, 6701
Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301-451-
3493, rahmanl@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, (HHS)
Dated: January 16, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-275 Filed 1-24-08; 8:45 am]
BILLING CODE 4140-01-M
